Clinical Trial Update: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function [Phase 2]

View source ↗

Summary

Phase 2 trial update showing results for Nedosiran in pediatric patients from birth to 11 years with Primary Hyperoxaluria (Types 1–3); the study is completed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria
• Hyperoxaluria Type

Drugs mentioned

• nedosiran (nedosiran)

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2026-04-16